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Abstract As in other brain tumors, multiple recurrences after complete resection and irradi-
ation of supratentorial ependymoma are common and frequently result in patient death.
This standard-of-care treatment was established in the pregenomic era without the ability
to evaluate the effect that mutagenic therapies may exert on tumor evolution and in pro-
moting resistance, recurrence, and death. We seized a rare opportunity to characterize
treatment effects and the evolution of a single patient’s ependymoma across four recur-
rences after different therapies. A combination of high-depth whole-genome and exome-
basedDNA sequencing of germline and tumor specimens, RNA sequencing of tumor spec-
imens, and advanced computational analyses were used. Treatment with radiation and che-
motherapies resulted in a substantial increase in mutational burden and diversification of
the tumor subclonal architecture without eradication of the founding clone. Notable
somatic alterations included a MEN1 driver, several epigenetic modifiers, and therapy-in-
duced mutations that impacted multiple other cancer-relevant pathways and altered the
neoantigen landscape. These genomic data provided new mechanistic insights into the
genesis of ependymoma and pathways of resistance. They also revealed that radiation
and chemotherapy were significant forces in shaping the increased subclonal complexity
of each tumor recurrence while also failing to eradicate the founding clone. This raises
the question of whether standard-of-care treatments have similar consequences in other pa-
tients with ependymoma and other types of brain tumors. If so, the perspective obtained by
real-time genomic characterization of a tumormay be essential for making effective patient-
specific and adaptive clinical decisions.
[Supplemental material is available for this article.]
INTRODUCTION
Ependymomas are a heterogeneous group of primary central nervous system (CNS) tumors
with multiple histological, brain region, age, and molecular features distinguishing between
different prognostic groups (Pajtler et al. 2015; Dorfer et al. 2016; Khatua et al. 2017). Based
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on standard histological features, ependymal neoplasms can be diagnosed as World Health
Organization (WHO) Grade I, II, or III tumors. However, in contrast to other brain tumors,
histological grading has proven to be aweak prognostic indicator of outcome for ependymo-
mas (Pajtler et al. 2017). In the largest published study of ependymoma outcome involving
282 patients, gross total resection (GTR) was the only prognostic factor associated with in-
creased survival (Vera-Bolanos et al. 2015). Strikingly, in this study, GTR and postsurgical ra-
diation therapy associated with a shorter progression-free survival than GTR alone. These
data indicate that, as yet, we do not know enough about the molecular mechanisms of epen-
dymoma, or about the appropriate indications for, and most effective modes of, adjuvant
therapies.
A means to generating the necessary insights to address these concerns is comparative
genomic analyses of primary and posttreatment specimens. To date, there is a paucity of in-
formation regarding the genomic changes in ependymomas that recur serially through mul-
tiple treatment regimens. This is largely due to the rarity of the disease and a failure to
consistently bank and analyze recurrent samples. To determine the temporal genomic
changes that occurred in one patient’s ependymoma disease as it recurred after several dif-
ferent therapeutic modalities, we characterized the genomic landscape of serial resections
with high-depth whole-genome and exome sequencing. These data provided an evaluation
of putative driver mutations, mutational signatures resulting from therapy, mechanisms for
therapy response and resistance, and shifts in the neoantigen profile from the initial disease
presentation through four recurrences.
CLINICAL PRESENTATION AND FAMILY HISTORY
The initial diagnosis was made in a 16-yr-old right-handed female who presented to the
St. Louis Children’s Hospital Emergency Department with a 3-d history of headache and
vomiting (Table 1). Magnetic resonance imaging (MRI) scan revealed a 6 × 4 cm enhancing
mass in the right frontotemporal region (Fig. 1A, initial diagnosis). The patient underwent a
GTR via a right frontotemporal craniotomy. Pathological evaluation was significant for a
hypercellular glial tumor with prominent pseudo-rosettes, increased mitoses, vascular
Table 1. Clinical history
Date Event
Month 1 Initial GTR of anaplastic ependymoma WHO Grade III
Months 2–3 Irradiation of tumor bed to 59.4 Gy
Month 45 GTR of first recurrent anaplastic ependymoma
Months 47–48 Reirradiation with 59.4 Gy with 10 months of temozolomide
Months 48–58 Temozolomide chemotherapy
Month 63 GTR of second recurrent anaplastic ependymoma
Month 65 Lapatinib and Avastin therapy initiated
Month 69 Lapatinib discontinued secondary to toxicity
Month 77 Avastin discontinued
Month 83 GTR of third recurrence of anaplastic ependymoma
Months 84–104 Avastin therapy
Month 104 GTR of fourth recurrent anaplastic ependymoma
GTR, gross total resection; WHO, World Health Organization.
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proliferation and necrosis, and perinuclear dot-like expression of epithelial membrane anti-
gen (EMA) (Fig. 1B,C) along with diffuse glial fibrillary acidic protein immunoreactivity. A
diagnosis of anaplastic ependymoma (WHO Grade III) was made. Evaluations for CNS dis-
semination were negative. The patient received 59.4 Gy of fractionated photon irradiation
to the tumor bed plus a 1-cm margin, which is standard for supratentorial ependymoma.
Forty-four months after the initial diagnosis, the patient suffered a seizure and an MRI re-
vealed a 13 × 15 × 16 mm nodular recurrence in the right frontal lobe along the posterior
margin of the initial resection cavity (Fig. 1A, first recurrence). MRI of spine and cerebrospinal
fluid cytology were negative. The patient underwent complete resection of the recurrent tu-
mor, which exhibited similar histology to the initial tumor. The resection cavity and margin
were reirradiated with an additional 59.4 Gy of fractionated photon irradiation and the pa-
tient received 10 mo of standard dose temozolomide treatment.
A surveillance scan 17 mo after the second resection demonstrated a 7-mm enhancing
nodule in the temporal surface of the right sylvian fissure near the resection cavity, consistent
with recurrence (Fig. 1A, second recurrence). Following a third complete resection, histopa-
thology was again consistent with anaplastic ependymoma and analysis for dissemination
was negative. The patient was enrolled on CERN-0801 at Children’s Memorial Hospital in
Chicago and received combined Avastin and lapatinib. Lapatinib was discontinued 4 mo lat-
er because of toxicity, and Avastin was continued for an additional 8 mo for a total of 1 yr of
treatment every 2 wk. Six months later, an MRI revealed a new right perisylvian lesion and
right thalamic enhancing nodule (Fig. 1A, third recurrence). Complete resection of the peri-
sylvian lesion was performed and pathology again indicated anaplastic ependymoma (Fig.
1D) with no evidence of dissemination. Avastin was restarted and continued for 20 mo until
Figure 1. Radiographic and pathological evaluation of initial and recurrent ependymoma. (A) Serial MRIs over
a 9-yr period demonstrating a heterogeneously enhancing mass in the right frontotemporal region at the time
of initial diagnosis and four enhancing recurrent lesions adjacent to the initial resection cavity. (B) Hematoxylin
and eosin (H&E) stain of formalin-fixed paraffin-embedded primary resection material revealed a densely cel-
lular tumor with increased mitotic activity, necrosis, and microvascular proliferation. (C ) Immunostain for epi-
thelial membrane antigen (EMA) shows multifocal perinuclear dot-like positivity, which is characteristic of
ependymal differentiation along with concomitant cytoplasmic expression of glial fibrillary acidic protein
(not shown). (D) H&E stain of each recurrent tumor revealed persistence of the ependymal phenotype.
Pictured is the third recurrence. All the photomicrographs are taken at 40× magnification.
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new evidence from serial MRI indicated progression in a perisylvian lesion that had remained
following themost recent surgery (Fig. 1A, fourth recurrence). This lesion also was complete-
ly resected and diagnosed as anaplastic ependymoma. The patient continues on treatment
at the time of this report, >11 yr from original diagnosis, without evidence of dissemination
beyond this loco-regional area.
GENOMIC ANALYSES
Analysis of the Matched Normal Sample
To determine whether the patient possessed a germline predisposition to cancer, we
analyzed the sequence data obtained from her leukocyte-derived DNA (normal,
Supplemental Table S1) and identified 176 protein-altering constitutional variants that
were rare in the population and fell into highly damaging classes of mutations (frameshifts,
nonsense, nonstop, or splice-site). Variants were observed in several genes known to be
important for immune function, including splice site SNPs in RAG1, HLA-DRB1, and HLA-
DRB5, as well as a nonsense mutation in HLA-DRB5. Several cancer-relevant genes were
also observed: splice-site alterations in DDX3X (Dahlin et al. 2015) and MAD2L2 (alias:
REV7) (Boersma et al. 2015; Xu et al. 2015) and in-frame insertions in MNX1 (Das 2016)
and ZFHX3 (Mabuchi et al. 2010). Some with direct glioma relevance were also observed:
FOXD1 (in-frame deletion) (Koga et al. 2014; Cheng et al. 2016; Gao et al. 2017), BCL2L2
(SNP) (Chung et al. 2015), and RYK (frameshift insertion) (Adamo et al. 2017). Although
MNX1 functions as an oncogene to promote pancreatic islet cell tumors in multiple
endocrine neoplasia type 1 (MEN1) (Scacheri et al. 2006), this particular mutation is common
in the population and unlikely to be relevant to predisposition.
Landscape of Somatic Mutations during Disease Progression
We identified 1332 somatic mutations across the five resection specimens, 162 of which
were in protein-coding regions, and 110 of which were nonsilent (Fig. 2; Supplemental
Table S2). The primary tumor sample contained only one overtly cancer-related gene muta-
tion, an expressed frameshift insertion inMEN1 (K237fs) (Table 2). We also observed several
large copy-number alterations (CNAs) in this sample, including deletions of 6p, 15q, 22, and
the first 22 Mb of Chromosome 1, that were shared with the recurrent tumors (Supplemental
Fig. S1, Table S3). Chromosome 11 was heavily rearranged, with multiple distinct regions of
amplification and deletion, one of which deleted the second copy ofMEN1. Integrated anal-
ysis of the DNA and RNA did not detect any gene fusion events, although many putative
structural variants were detected (Supplemental Tables S4 and S5).
All SNVs, indels, and CNAs found in the initial resection were retained in the first recur-
rence, which was diagnosed after radiation therapy and a 44-mo interval. An additional 12
new protein-coding somatic mutations were identified in the recurrent tumor, including a
nonsense mutation in DEPDC5, an inhibitor of mTORC signaling. Missense mutations
were observed in KREMEN2 (G165V), a gene that has been linked to melanoma, and in
BANP (N223S), an epigenetic regulator. None is obviously expressed in this tumor, but
the variants in both KREMEN2 and BANP are expressed in subsequent tumors with higher
quality and higher-depth RNA-seq, so it is likely that these variants are expressed below
our level of sensitivity in this resection sample. Mutated DEPDC5 may have been undetect-
able because of undergoing nonsense-mediated decay.
The second recurrent tumor emerged after additional radiation therapy and treatment
with temozolomide. It was resected and the genomic analysis of this specimen indicated
that essentially all previously observed mutations were retained, with the exception of
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two low-VAF protein-coding variants from the previous recurrence, including loss of the
DEPDC5 nonsense mutation. An additional 66 protein-coding SNVs and indels were ac-
quired, including a 19-bp frameshift deletion in GPR124 and low-VAF missense mutations
in SEPT5 (T260A), MAP4K3 (F300S), and KAT6B (P1276L). Of these, only the MAP43K
and KAT6B mutations were observably expressed. The copy-number landscape was
identical to the previous tumors, with the exception of a new homozygous deletion on
Chromosome 2p.
The third recurrence occurred after treatment with Avastin and lapatinib. Genomic anal-
ysis of this resection specimen revealed that all coding mutations specific to the second re-
currence, including the Chromosome 2 copy-number loss, were undetectable at the third
recurrence. In contrast, virtually all mutations identified in the first two resections persisted,
the only exception being two low-VAF events in MYH10 and OR1L1. Fifty-six new protein-
coding mutations were acquired, including missense mutations in POU3F4 (P568T), an epi-
genetic regulator,OTUD5 (P338L), a p53 activator, and SPRY3 (R19C), a regulator of FGF sig-
naling. None has been previously implicated in ependymoma, and their relevance for
disease progression and therapy resistance is unclear.
The fourth recurrence was resected after continued Avastin treatment. In this sample, 29
of the protein-codingmutations newly acquired in the prior (third) recurrence were no longer
detected, but 18 new protein-coding mutations were identified. These included nonsense
mutations in CREB3L3 and NF2, a gene previously linked to ependymoma. A missense mu-
tation in the chromatin/transcriptional regulator PATZ1 was also observed. In addition to the
NF2mutation, we identified two point mutations that potentially impact Hippo pathway sig-
naling in LATS1 and MAP4K3 (Meng et al. 2015; Oh et al. 2015).
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Figure 2. Variant allele fractions of nonsilent mutations in protein-coding genes in all five resections.
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Clonal Heterogeneity and Mechanisms of Tumor Evolution
To characterize the changing clonal architecture of this tumor, the variant allele fractions of
copy-number neutral SNVs were clustered in five dimensions using the sciClone algorithm
(Fig. 3A). Eight clusters were detected, and the mutation spectrum for each was identified.
The first recurrent tumor after radiation therapy was dominated by cluster 2, which
emerged from a population of cells undetectable in our analysis of the original biopsy
data (with a sensitivity of ∼2% VAF). The mutation spectrum shows a notable decrease
in C>T transitions in cluster 2, when compared with those in cluster 1 from the original
tumor (Fig. 3B).
In the second recurrence, following additional radiation and treatment with temozolo-
mide, we identified the emergence of two new subclonal populations (clusters 3 and 4)
that were likewise undetectable in the prior two samples’ data. Cluster 4, and all subse-
quently appearing clusters, each have a significantly higher proportion of A>G transitions
than the founding clone, a pattern consistent with temozolomide-induced mutagenesis
(all P < 0.03) (Supplemental Table S6; Bodell et al. 2003). In the third recurrence, following
Avastin treatment, both clusters 3 and 4 were undetectable, but clusters 5 and 6 emerged.
Although cluster 6 was cleared in the final resection sample we studied, cluster 5 persisted
and two rare subclonal populations expanded into clusters 7 and 8, which make up a
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Figure 3. (A) Subclonal clustering of the five tumor samples. Points represent the VAFs of individual SNVs at
each time point, and lines connect the mean VAF of each cluster in each sample. Each sample is labeled with
the number of detectable mutations at that time point. (B) Mutation spectrum of each cluster. (C ) The number
of high-quality MHC Class I neoantigens found in each subclonal population.
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substantial portion of the final tumor. Some mutations in these two clusters were just above
the level of detection in the third resection.
Though there were too few mutations to perform per-cluster mutational signature anal-
ysis (Rosenthal et al. 2016), we did compare the deletion/substitution ratio between muta-
tions that predated irradiation (cluster 1) and those that arose after radiotherapy (clusters
2–8). We observed a significant increase in the proportion of deletions postirradiation
(Pearson’s χ2 P = 1.657 × 10−05), a finding that is consistent with previously reported muta-
tional signatures of ionizing radiation (Behjati et al. 2016).
In addition to identifyingmutations correlatedwith specific subclonal expansions, wealso
examined the expression of O6-methylguanine DNA methyltransferase (MGMT), which is
known to drive brain tumor recurrence through increased expression in post-temozolomide
lesions (Bocangel et al. 2002; Hegi et al. 2005). In this case, MGMT RNA expression levels
were not clearly correlated with the emergence of post-temozolomide recurrences, suggest-
ing that they relied upon alternative mechanisms of resistance (Supplemental Fig. S2).
Evolving Landscape of Targets for Immunotherapy
To understand how the immunogenicity of this tumor evolved over the course of treatment,
we applied the pVACSeq neoantigen prediction pipeline (Hundal et al. 2016) to the protein-
altering mutations that we observed in each tumor studied. The patient’s HLA haplotypes
were inferred to be A∗24:02, A∗26:01, B∗40:02, B∗38:01, C∗12:03, and C∗03:05. We identi-
fied only 14 expressedmutations that produce “high-quality” predictedMHCClass I neoan-
tigens (Fig. 2C), which we define as having median binding affinity (ic50) of <500 nM, and
with a higher binding affinity to the mutant than the wild-type peptide (Supplemental
Table S7). As overall mutation burden is highly correlated with neoantigen load, this is per-
haps unsurprising. Only three neoantigens were present in the founding clone, whereas 11
of the 14 were specific to a subclonal population and therefore not present in all cells of the
tumor.
DISCUSSION
In this study, we found that standard-of-care and experimental approaches to treatment of an
ependymoma increased its mutational burden and diversified its subclonal architecture. The
diagnosis of a supratentorial anaplastic ependymoma, not arising from the ventricles, is un-
common. Ependymomas, which occur in both pediatric and adult patients, display age-de-
pendent patterns of location and histology. Overall, the majority of ependymomas occur in
the spine, though this location is involved in only 20% of pediatric cases (McGuire et al.
2009a, 2009b). As was evident in this case, supratentorial ependymomas are most common
in older children and adolescents. In addition, anaplastic histology is also more common in
pediatric cases. Recent genomic analyses have indicated that most supratentorial anaplastic
ependymomas are associated with fusion events involving RELA or YAP1 (Pajtler et al. 2015).
Neither of these fusion events was detected in this case.
The Role of MEN1 Mutations
Notable in the evaluation of the primary diagnostic specimen was the biallelic somatic dis-
ruption of MEN1. MEN1 mutations, typically biallelic, have been infrequently reported in
ependymoma, both in the context of familial MEN1 syndrome and sporadically (Kato
et al. 1996; Urioste et al. 2002; Al-Salameh et al. 2010; Lee et al. 2016b), and appear to occur
in both high- and low-grade tumors of any location. Although MEN1 mutation has been as-
sociated with recurrence and progression from grade II to III ependymoma (Urioste et al.
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2002; Funayama et al. 2013), we offer the first clear evidence that MEN1 mutation is a driver
of the founding clone.
Functionally, MEN1 mutations are known to increase DNMT1 activity, which leads to
global increases in CpG island methylation, a characteristic of other tumors (Funayama
et al. 2013; Mack et al. 2014; Yuan et al. 2016), and silences key tumor suppressor genes,
including CDKN1B, CDKN2A, APC, and RASSF1A (Karnik et al. 2005; Lindberg et al.
2008; Juhlin et al. 2010). Coupled with the observed mutations in other epigenetic regula-
tors, these data add new evidence for epigenetic dysregulation in the genesis and progres-
sion of ependymoma.
Loss of menin function also leads to activation of the RAS (Wu et al. 2012), MAP kinase
(Gallo et al. 2002), PI3 kinase (Wang et al. 2011), Sonic Hedgehog (Gurung et al. 2013),
Wnt (Cao et al. 2009), and TGF-β signaling pathways, all with established roles in gliomagen-
esis (Matkar et al. 2013). Their role is underscored by the accumulation of mutations in addi-
tional regulators of their activation during the course of this tumor’s treatment: MAPK
(SPRY3) (Cabrita and Christofori 2008), PI3K (DEPDC5) (Cabrita and Christofori 2008; Bar-
Peled et al. 2013), and WNT (KREMEN2, NET1, GPR124) (Orlow et al. 1987; Mao et al.
2002; Posokhova et al. 2015; Wei et al. 2017).
Drivers of Recurrence and Susceptibility
Although more cases will be needed to confidently identify the specific mutations that drive
the expansion of therapy resistant subclones, the Hippo pathway stands out as a compelling
potential driver of the fourth recurrence, induced by newmutations in LATS1 (missense) and
inNF2 (nonsense).NF2 loss-of-function mutations have been previously associated with spi-
nal ependymomas (Lee et al. 2016a), and recent evidence suggests that YAP1, the nuclear
target of Hippo signaling, mediates aberrant proliferation upon NF2 loss during tumorigen-
esis (Shi et al. 2016). Furthermore, oncogenic YAP1 activation occurs as a consequence of a
loss inNF2-dependent inactivation of LATS1 (a key inhibitor of YAP1), and decreased LATS1
activity has also been associated with glioma progression (Ji et al. 2012; Oh et al. 2015; Shi
et al. 2016). YAP1 fusions are a key characteristic of one subgroup of supratentorial ependy-
momas (Archer and Pomeroy 2015) and we hypothesize that these mutations may represent
convergent evolution, producing similar phenotypic effects via a different mechanism.
Only one substantial subclone was clearly responsive to therapy (cluster 3) and it was
eradicated after treatment of recurrence 2 with Avastin and lapatinib. Among the compelling
target mediators of response or biomarkers of response is the mutation in GPR124. This or-
phan member of the adhesion G protein–coupled receptor family is required specifically for
the development of the brain vasculature in a VEGF-dependent manner (Kuhnert et al. 2010;
Cullen et al. 2011; Zhou and Nathans 2014), and GPR124 may be a biomarker of Avastin re-
sponse (Wang et al. 2014). GPR124 activates canonical Wnt signaling, which, as described
above, is normally directly inhibited by MEN1 and KREMEN2. The genes for both of these
proteins were mutated in this tumor, suggesting a model for Avastin response that might in-
volve enhanced activation of a VEGF–Wnt axis.
Changes to the Neoantigen Landscape during Progression
Overall, the number of expressed MHC Class I neoantigens that we predicted was low, as
expected in a tumor with only 110 protein-altering mutations. The presence of a relatively
high burden in the founding clone suggests that mechanisms of immune evasion were al-
ready present when the initial tumor presented and may explain why there was no relation-
ship between neoantigen load and subclonal response in subsequent tumors. This is
supported by the observation that expression markers of T-cell activation were low in all
five tumors.
Treatment-linked resistance in an ependymoma
C O L D S P R I N G H A R B O R
Molecular Case Studies
Miller et al. 2018 Cold Spring Harb Mol Case Stud 4: a002444 11 of 18
 Cold Spring Harbor Laboratory Press on October 5, 2019 - Published by molecularcasestudies.cshlp.orgDownloaded from 
Origin of New Subclones in Later Recurrences
Although we present evidence suggesting that radiation and temozolomide treatment in-
creased the mutation burden of this tumor, new mutations continued to be observed after
their use was discontinued. It is important to note that this is not necessarily indicative of a
continued elevated mutation rate. Mutations first observed in the last two recurrences
may have existed at very low frequencies in prior time points, and the observed mutation
spectrum in the new subclones is consistent with damage from previous therapies. Our prior
work with ultradeep sequencing suggests that many rare subclones often exist in a tumor
(with neutral fitness) and only become detectable after their fitness increases, either via ac-
quisition of one or more driver mutations or because the therapeutic regimen changes the
environment (Griffith et al. 2015b; Uy et al. 2017).
Future Directions
These results suggest that radiation and chemotherapy contributed to the increasing com-
plexity of this tumor by both adding to the mutational burden and expanding the subclonal
architecture. Determining whether this natural history is generally true in ependymoma pro-
gression, andwhat impact therapy-induced tumor evolution has on outcome, is an important
area of investigation with the potential to alter how we treat patients with both completely
resected supratentorial ependymoma and other brain tumors that are treatedwith irradiation
but frequently recur. In the largest published study of ependymoma outcome involving 282
patients, GTR was the only prognostic factor associated with increased survival (Vera-
Bolanos et al. 2015). In that analysis, GTR and postsurgical radiation therapy were associated
with a shorter progression-free survival than GTR alone. Data presented here raise the alarm-
ing hypothesis that time-to-progression was shortened because irradiation promoted tumor
evolution.
These clinical observations together with the sequencing-based characterizations pre-
sented here suggest that under some circumstances, adjuvant therapymay not be providing
a benefit, and indeed may hasten recurrence by promoting molecular diversification of the
tumor. We propose that this phenomenon be studied prospectively. In particular, our data
suggest that completely resected supratentorial ependymomas, and possibly other brain tu-
mors, should be sequenced at the time of diagnosis and again if there is a recurrent tumor.
Over time, this might reveal the genotypes for which radiation therapy eradicates the found-
ing clone, resulting in a cure, and in those for which it does not, but instead contributes to
evolving tumor complexity. Ultimately, it may be prudent to initially observe those patients
with complete resections without additional therapy or to treat those patients whose tumors
are likely to evolve in response to radiation therapy with targeted agents only as dictated by
genomic analysis. Critically important to this effort will be the use of unbiased sequencing
approaches like whole-exome or whole-genome sequencing rather than sequencing of tar-
geted gene panels. Although identification of druggable targets is important, it may be
equally important to construct more global models of tumor evolution.
Finally, it will be important to investigate further the utility of genomic characterization to
inform therapeutic options in this disease type. Although not all of the variants we identified
were “druggable” in the classical sense, a subset were found to comprise predicted high-af-
finity neoantigen targets that, ultimately, formed the basis of a polyvalent personalized vac-
cine, administered after recurrence 4. Such cancer immunogenomics approaches to clinical
care are only made possible through comprehensive genomic approaches to tumor charac-
terization. Although the efficacy of these treatments awaits large-scale studies and clinical
trials that are ongoing, our case highlights the potential to consider the pursuit of a person-
alized vaccine in extremely challenging settings of multiply recurrent disease such as the one
herein, where few to no other options exist.
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METHODS
DNA Sequencing
DNAwas isolated from fresh frozen sections of each tumor resection using theQIAGENDual
Prep and evaluated for quality and concentration using established methods. DNA was iso-
lated from PBMC after Ficoll-based isolation to provide a normal comparator and was eval-
uated for quality and concentration. Using 500 ng input for all five tumors and the blood
normal DNA, we generated two indexed whole-genome sequencing libraries by standard
methods (Kapa Biosystems) for each sample. One library per sample was processed through
exome hybrid capture using the IDT xGEN research exome capture reagent (Integrated
DNA Technologies), quantitated and amplified postcapture using the manufacturer’s proto-
col. Each of the correspondingWGS libraries was amplified by PCR, quantitated, and diluted
as appropriate for Illumina sequencing. The final libraries for each sample (WGS + exome)
were pooled to produce combined tumor and normal WGS- and exome-sequencing data
in a specific proportion, yielding ∼10-fold WGS and ∼1000-fold exome coverage
(Supplemental Table S1). The resulting library pools were loaded onto the HiSeqX platform
and sequenced using 150-bp paired end reads.
Somatic Variant Analysis
After index-based binning of the reads into WGS- and exome-derived tumor and normal
data, sequence data were aligned to reference sequence build GRCh37-lite-build37 using
BWA-mem (Li, H. arXiv:1303.3997 [q-bio.GN]) version 0.7.10 (params: -t 8::), then merged
and deduplicated using Picard version 1.113 (https://broadinstitute.github.io/picard/).
Somatic variants were called from the combined data using our Genome Modeling
System (Griffith et al. 2015a) as follows.
SNVs were detected using the union of four callers: (1) SAMtools (Li et al. 2009) version
r982 (params: mpileup -BuDs) intersected with Somatic Sniper (Larson et al. 2012) version
1.0.4 (params: -F vcf –G -L -q 1 -Q 15) and processed through false-positive filter v1 (params:
–bam-readcount- version 0.4 –bam-readcount-min-base-quality 15 –min-mapping-quality
40 –min-somatic-score 40), (2) VarScan (Koboldt et al. 2012) version 2.3.6 filtered by varscan-
high-confidence filter version v1 and processed through false-positive filter v1 (params:
–bam-readcount-version 0.4 –bam-readcount-min-base-quality 15), (3) Strelka (Saunders
et al. 2012) version 1.0.11 (params: isSkipDepthFilters = 0), and (4) Mutect (Cibulskis et al.
2013) v1.1.4.
Indels were detected using the union of three callers: (1) GATK (McKenna et al. 2010)
somatic-indel version 5336; (2) VarScan version 2.3.6 filtered by varscan-high-confidence-
indel version v1, and (3) Strelka version 1.0.11 (params: isSkipDepthFilters = 0).
SNVs and Indels were further filtered by removing artifacts found in a panel of 905
normal exomes, removing sites that exceeded 0.1% frequency in the 1000 genomes or
NHLBI exome-sequencing projects, and then using a Bayesian classifier (https://github.
com/genome/genome/blob/master/lib/perl/Genome/Model/Tools/Validation/Identify
Outliers.pm) and retaining variants classified as somatic with a binomial log-likelihood of at
least 10.
For protein-coding mutation counts described in the results below, a variant was consid-
ered to be present in a sample if it appeared with at least three variant supporting reads and
a VAF of >2.5%. As some sites had low or variable coverage, a variant was only considered to
be completely cleared if it did not appear in any subsequent samples.
Copy-number aberrations were detected using bam-window (window-size 10,000) and
copy-cat version 1.6.11 (params: –per-read-length –per-library) (https://github.com/
chrisamiller/copyCat). Uneven sequence coverage of the normal sample required us to
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run copyCat in tumor-only mode, followed by manual review to differentiate somatic from
germline copy-number events.
Putative structural variants were detected using the union of BreakDancer 1.4.5 (Chen
et al. 2009) filtered by novo-realign and tigra-sv, and squaredancer 0.1 (https://github.
com/genome/genome/blob/master/lib/perl/Genome/Model/Tools/Sv/SquareDancer.pl).
RNA Sequencing
Total RNA was concurrently isolated from each fresh frozen tumor resection (QIAGEN Dual
Prep), and evaluated for quality and concentration using the Agilent Tapestation. RNA-seq
libraries were constructed using the TruSeq Stranded RNAseq library kit (Illumina, Inc.) ac-
cording to the manufacturer’s protocol, quantitated and diluted for sequencing. Using the
HiSeq 2500, we produced sequencing data from each RNA-seq library in a single flow cell
lane by paired end 100 bp reads, yielding between 96 and 655 million reads per sample.
The fourth recurrence sample was subjected to a capture step before sequencing, using
the IDT xGEN research exome capture reagent. This sample yielded 856 million reads,
with a much higher coding-region percentage (Supplemental Table S1).
RNA-seq Analysis
The resulting read data were aligned to the human reference with TopHat v2.0.8 (denovo
mode, params: –library-type fr-firststrand –bowtie-version=2.1.0). Expression levels were cal-
culated with Cufflinks v2.1.1 (params: –max-bundle-length 10000000 –max-bundle-frags
10000000) (Trapnell et al. 2012).
Gene Fusions
Gene fusions were detected from RNA and DNA using Integrate v0.2.0 (Zhang et al. 2015)
with default parameters.
Heterogeneity Analysis
Using the high depth of coverage from combining exome and WGS data sets for these tu-
mors, we characterized the heterogeneity of each tumor specimen and compared it to the
others in the series. Here, copy-number-neutral variants and their attendant VAFs were clus-
tered in five dimensions using the sciClone algorithm v1.1 (Miller et al. 2014) (parameters:
minimumDepth = 300, maximumClusters=15), followed by phylogeny reconstruction with
clonEvol (Dang et al. 2017).
Neoantigen Predictions
Somatic mutations and RNA-seq data from tumors were input into our pVACSeq pipeline
(Hundal et al. 2016). WGS data from the normal blood was used to identify the patient’s
HLA haplotypes for Class I, using Laminar (Warren et al. 2012). MHC Class I binding predic-
tions were generated through pVACSeq using NetMHC v3.4, as well as five other algorithms
from the Immune Epitope Database and Analysis resource (IEDB, iedb.org): netMHC,
netmhccons, netmhcpan, pickpocket, smm, and smmpmbec. Predictions were retained if
the median score had an ic50 < 500 and better binding of the mutant peptide than the
wild type (fold-change > 1). Results were then filtered to require expression of the mutant
allele (FPKM > 1 and at least one variant-supporting read in the RNA). These combined
data sets were used to identify neoantigenic peptide sequences in all five tumor samples,
as illustrated in Figure 3C.
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Pathology Methods
All the resection specimens (original and recurrences) were handled as regular surgical neu-
ropathology cases. Although H&E stain and Ki-67 immunostain were performed on all the
specimens, glial fibrillary acidic protein and EMA were limited to the initial and 2014
resections.
ADDITIONAL INFORMATION
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